Acadia Pharmaceuticals (ACAD) said Tuesday in a regulatory filing that 2025 net sales are expected to exceed $1 billion, consistent with prior guidance.
Analysts polled by FactSet expect $1.08 billion.
In a statement, the company projected 2028 sales of $1.7 billion as part of business updates presented at the JPMorgan Healthcare Conference in San Francisco.
Analysts polled by FactSet expect $1.48 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments